13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001674546
Total reported value
$4.8B
$4.8B
148 檔
25.4%
The Q1 2025 SEC filing reveals that Bellevue Group AG held a total portfolio value of $4.8B, covering 148 public equity positions.
In Q1 2025, Bellevue Group AG displayed an active expansion posture, initiating 148 new positions and adding to 0 existing holdings, outstripping position reductions.
In terms of portfolio concentration, the top 5 core holdings (including ARGX, IONS, SYK) accounted for 25.4% of total reported equity market value during Q1 2025.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | ARGX | Argenx Se - Adr | Stock-Healthcare | 7.68% | +0.44% | -2.41% | |
| 2 | IONS | Ionis Pharmaceuticals Inc | Stock-Healthcare | 5.31% | -1.63% | -0.20% | |
| 3 | SYK | Stryker CORP | Stock-Healthcare | 4.73% | +0.08% | +8.96% | |
| 4 | ISRG | Intuitive Surgical Inc | Stock-Healthcare | 4.72% | -1.01% | -8.32% | |
| 5 | ALNY | Alnylam Pharmaceuticals Inc | Stock-Healthcare | 4.65% | -1.84% | -0.28% | |
| 6 | ABT | Abbott Laboratories | Stock-Healthcare | 4.63% | -1.00% | -7.85% | |
| 7 | NBIX | Neurocrine Biosciences Inc | Stock-Healthcare | 4.51% | +0.08% | — | |
| 8 | VRTX | Vertex Pharmaceuticals Inc | Stock-Healthcare | 4.49% | -1.20% | -15.26% | |
| 9 | BSX | Boston Scientific CORP | Stock-Healthcare | 4.41% | -1.39% | -8.63% | |
| 10 | RVMD | Revolution Medicines Inc | Stock-Healthcare | 3.47% | +0.56% | -0.29% | |
| 11 | INCY | Incyte CORP | Stock-Healthcare | 2.84% | — | -3.05% | |
| 12 | AGIO | Agios Pharmaceuticals Inc | Stock-Other | 2.31% | — | — | |
| 13 | UNH | Unitedhealth Group Inc | Stock-Healthcare | 1.93% | +0.35% | +3.15% | |
| 14 | MDT | Medtronic plc | Stock-Healthcare | 1.89% | -0.33% | -10.03% | |
| 15 | SRRK | Scholar Rock Holding CORP | Stock-Other | 1.81% | -1.36% | -0.15% | |
| 16 | BDX | Becton Dickinson And Co | Stock-Healthcare | 1.77% | -0.11% | +2.00% | |
| 17 | DXCM | Dexcom Inc | Stock-Healthcare | 1.63% | -0.01% | +1.82% | |
| 18 | PODD | Insulet CORP | Stock-Healthcare | 1.60% | -0.41% | -15.73% | |
| 19 | EW | Edwards Lifesciences CORP | Stock-Healthcare | 1.58% | -0.19% | -11.47% | |
| 20 | CLDX | Celldex Therapeutics Inc | Stock-Other | 1.25% | +0.03% | — | |
| 21 | PEN | Penumbra Inc | Stock-Healthcare | 1.23% | -0.10% | EXIT | |
| 22 | AKRO | Akero Therapeutics Inc | Stock-Other | 1.13% | — | — | |
| 23 | BHVN | Biohaven Ltd. | Stock-Other | 1.10% | — | — | |
| 24 | BEAM | Beam Therapeutics Inc | Stock-Other | 1.05% | — | +57.82% | |
| 25 | MRNA | Moderna Inc | Stock-Healthcare | 0.96% | — | -5.17% | |
| 26 | GEHC | GE Healthcare Technology | Stock-Healthcare | 0.95% | -0.37% | — | |
| 27 | CI | THE Cigna Group | Stock-Healthcare | 0.87% | -0.23% | -6.13% | |
| 28 | RMD | Resmed Inc | Stock-Healthcare | 0.83% | -0.24% | +3.12% | |
| 29 | IMCR | Immunocore Holdings Plc-adr | Stock-Other | 0.81% | -0.15% | +1.35% | |
| 30 | LLY | Eli Lilly & Co | Stock-Healthcare | 0.81% | +0.01% | -4.00% | |
| 31 | WVE | Wave Life Sciences Ltd. | Stock-Other | 0.74% | — | EXIT | |
| 32 | ZBH | Zimmer Biomet Holdings Inc | Stock-Healthcare | 0.74% | -0.10% | -0.77% | |
| 33 | IDXX | Idexx Laboratories Inc | Stock-Healthcare | 0.72% | -0.51% | -0.05% | |
| 34 | TMO | Thermo Fisher Scientific Inc | Stock-Healthcare | 0.72% | +0.09% | +5.36% | |
| 35 | EWTX | Edgewise Therapeutics Inc | Stock-Other | 0.70% | -1.15% | EXIT | |
| 36 | COO | Cooper Cos Inc/the | Stock-Healthcare | 0.67% | -0.16% | -0.03% | |
| 37 | ABBV | Abbvie Inc | Stock-Healthcare | 0.63% | -0.27% | +198.81% | |
| 38 | VEEV | Veeva Systems Inc-class A | Stock-Healthcare | 0.59% | -0.02% | -11.23% | |
| 39 | BMRN | Biomarin Pharmaceutical Inc | Stock-Healthcare | 0.58% | — | +11.96% | |
| 40 | DHR | Danaher CORP | Stock-Healthcare | 0.57% | -0.33% | +3.67% | |
| 41 | AMGN | Amgen Inc | Stock-Healthcare | 0.57% | +4.02% | -9.31% | |
| 42 | EXK | Exact Sciences CORP | Stock-Materials | 0.56% | — | -16.57% | |
| 43 | MOH | Molina Healthcare Inc | Stock-Healthcare | 0.56% | +0.13% | NEW | |
| 44 | STE | STERIS plc | Stock-Healthcare | 0.56% | -0.09% | — | |
| 45 | GMED | Globus Medical Inc - A | Stock-Healthcare | 0.55% | -0.27% | -8.44% | |
| 46 | PRCT | Procept Biorobotics CORP | Stock-Other | 0.54% | -0.06% | -10.36% | |
| 47 | ALGN | Align Technology Inc | Stock-Healthcare | 0.54% | -0.07% | -5.63% | |
| 48 | HCA | Hca Healthcare Inc | Stock-Healthcare | 0.48% | -0.24% | -0.12% | |
| 49 | MRK | Merck & Co. Inc. | Stock-Healthcare | 0.47% | -0.28% | -12.43% | |
| 50 | MCK | Mckesson CORP | Stock-Healthcare | 0.46% | -0.31% | +58.32% |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | ARGX | Argenx Se - Adr | — | NEW | New buy |
| 2 | IONS | Ionis Pharmaceuticals Inc | — | NEW | New buy |
| 3 | SYK | Stryker CORP | — | NEW | New buy |
| 4 | ISRG | Intuitive Surgical Inc | — | NEW | New buy |
| 5 | ALNY | Alnylam Pharmaceuticals Inc | — | NEW | New buy |
| 6 | ABT | Abbott Laboratories | — | NEW | New buy |
| 7 | NBIX | Neurocrine Biosciences Inc | — | NEW | New buy |
| 8 | VRTX | Vertex Pharmaceuticals Inc | — | NEW | New buy |
| 9 | BSX | Boston Scientific CORP | — | NEW | New buy |
| 10 | RVMD | Revolution Medicines Inc | — | NEW | New buy |
| 11 | INCY | Incyte CORP | — | NEW | New buy |
| 12 | AGIO | Agios Pharmaceuticals Inc | — | NEW | New buy |
| 13 | UNH | Unitedhealth Group Inc | — | NEW | New buy |
| 14 | MDT | Medtronic plc | — | NEW | New buy |
| 15 | SRRK | Scholar Rock Holding CORP | — | NEW | New buy |
| 16 | BDX | Becton Dickinson And Co | — | NEW | New buy |
| 17 | DXCM | Dexcom Inc | — | NEW | New buy |
| 18 | PODD | Insulet CORP | — | NEW | New buy |
| 19 | EW | Edwards Lifesciences CORP | — | NEW | New buy |
| 20 | CLDX | Celldex Therapeutics Inc | — | NEW | New buy |
| 21 | PEN | Penumbra Inc | — | NEW | New buy |
| 22 | AKRO | Akero Therapeutics Inc | — | NEW | New buy |
| 23 | BHVN | Biohaven Ltd. | — | NEW | New buy |
| 24 | BEAM | Beam Therapeutics Inc | — | NEW | New buy |
| 25 | MRNA | Moderna Inc | — | NEW | New buy |
| 26 | GEHC | GE Healthcare Technology | — | NEW | New buy |
| 27 | CI | THE Cigna Group | — | NEW | New buy |
| 28 | RMD | Resmed Inc | — | NEW | New buy |
| 29 | IMCR | Immunocore Holdings Plc-adr | — | NEW | New buy |
| 30 | LLY | Eli Lilly & Co | — | NEW | New buy |
| 31 | WVE | Wave Life Sciences Ltd. | — | NEW | New buy |
| 32 | ZBH | Zimmer Biomet Holdings Inc | — | NEW | New buy |
| 33 | IDXX | Idexx Laboratories Inc | — | NEW | New buy |
| 34 | TMO | Thermo Fisher Scientific Inc | — | NEW | New buy |
| 35 | EWTX | Edgewise Therapeutics Inc | — | NEW | New buy |
| 36 | COO | Cooper Cos Inc/the | — | NEW | New buy |
| 37 | ABBV | Abbvie Inc | — | NEW | New buy |
| 38 | VEEV | Veeva Systems Inc-class A | — | NEW | New buy |
| 39 | BMRN | Biomarin Pharmaceutical Inc | — | NEW | New buy |
| 40 | DHR | Danaher CORP | — | NEW | New buy |
| 41 | AMGN | Amgen Inc | — | NEW | New buy |
| 42 | EXK | Exact Sciences CORP | — | NEW | New buy |
| 43 | MOH | Molina Healthcare Inc | — | NEW | New buy |
| 44 | STE | STERIS plc | — | NEW | New buy |
| 45 | GMED | Globus Medical Inc - A | — | NEW | New buy |
| 46 | PRCT | Procept Biorobotics CORP | — | NEW | New buy |
| 47 | ALGN | Align Technology Inc | — | NEW | New buy |
| 48 | HCA | Hca Healthcare Inc | — | NEW | New buy |
| 49 | MRK | Merck & Co. Inc. | — | NEW | New buy |
| 50 | MCK | Mckesson CORP | — | NEW | New buy |
According to official SEC Form 13F filings, Bellevue Group AG reported a total U.S. public equity portfolio value of $4.8B across 148 disclosed positions in Q1 2025.
During Q1 2025, Bellevue Group AG's top holdings by market value included ARGX (7.7%)、IONS (5.3%)、SYK (4.7%). The largest single position, ARGX, represented 7.7% of total portfolio value.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
Top New Position Initiated
ARGX
市值: $342.6M
In Q1 2025, Bellevue Group AG made 148 total portfolio adjustments, initiating 148 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.